Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039099 | 0.84 | CTSS (0.42) | EPHX1ALDH1A1KMT2APYGLGAA | |
| SCHEMBL3037258 | 0.84 | CTSS (0.42) | EPHX1ALDH1A1KMT2APYGLGAA | |
| SCHEMBL16530174 | 0.82 | KMT2A (0.41) | EPHX1ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL15363245 | 0.82 | KMT2A (0.41) | EPHX1ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL5804741 | 0.80 | CA12 (0.41) | EPHX1ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL2273893 | 0.78 | EPHX1 (0.42) | EPHX1ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL4405382 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KMT2AMEN1PYGLHPGD | |
| SCHEMBL6896596 | 0.77 | EPHX1 (0.56) | EPHX1KMT2AMEN1GAACTSS | |
| SCHEMBL1328516 | 0.76 | TDP1 (0.46) | EPHX1ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL923552 | 0.75 | EPHX1 (0.54) | EPHX1ALDH1A1KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-1713822-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1713823-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-11-11 | — | — | EP | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713823-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | EPHX1 866/4885ALDH1A1 4288/4885KMT2A 4582/4885 |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | EPHX1 1839/4885ALDH1A1 4292/4885KMT2A 4532/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | EPHX1 1117/4885ALDH1A1 3955/4885KMT2A 4573/4885 |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | EPHX1 1839/4885ALDH1A1 4292/4885KMT2A 4532/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | EPHX1 2385/4885ALDH1A1 4156/4885KMT2A 4235/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | EPHX1 1839/4885ALDH1A1 4292/4885KMT2A 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.